dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Petrelli, Annalisa |
dc.contributor.author | rizzolio, sabrina |
dc.contributor.author | Pietrantonio, Filippo |
dc.contributor.author | bellomo, sara erika |
dc.contributor.author | Benelli, Matteo |
dc.contributor.author | de cecco, loris |
dc.contributor.author | Llop-Guevara, Alba |
dc.contributor.author | Serra, Violeta |
dc.date.accessioned | 2023-07-05T08:02:30Z |
dc.date.available | 2023-07-05T08:02:30Z |
dc.date.issued | 2023-05-15 |
dc.identifier.citation | Petrelli A, Rizzolio S, Pietrantonio F, Bellomo SE, Benelli M, De Cecco L, et al. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Cancer Res. 2023 May 15;83(10):1699–710. |
dc.identifier.issn | 1538-7445 |
dc.identifier.uri | https://hdl.handle.net/11351/9968 |
dc.description | Mutacions; Càncers gàstrics; Inhibidors de PARP |
dc.description.sponsorship | This work was funded by the Italian Association for Cancer Research (AIRC), IG 20210 and IG 27531 to S. Giordano; IG 23624 to F. Pietrantonio; IG 21770 to S. Corso. FPRC 5×1000 2015 Min. Salute “Strategy” to SG; Fondazione Piemontese per la Ricerca sul Cancro (FPRC) 5×1000 MS2017 PTCRC-intra 2020 to S. Giordano; Ricerca Locale Dept. Oncology 2021 to S. Corso; Italian Ministry of Health-Ricerca Corrente 2022–23. B. Pellegrino was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche and received research grants from GOIRC. Fondazione CR Firenze to M. Benelli. |
dc.language.iso | eng |
dc.publisher | American Association for Cancer Research |
dc.relation.ispartofseries | Cancer Research;83(10) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Anomalies cromosòmiques |
dc.subject | Estómac - Càncer - Tractament |
dc.subject | Estómac - Càncer - Aspectes genètics |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /therapeutic use |
dc.subject.mesh | Stomach Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Germ-Line Mutation |
dc.title | BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1158/0008-5472.CAN-22-2620 |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | neoplasias gástricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | mutación de la línea germinal |
dc.relation.publishversion | https://doi.org/10.1158/0008-5472.CAN-22-2620 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Petrelli A, Rizzolio S] Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. [Pietrantonio F] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Bellomo SE] Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. Department of Oncology, University of Torino, Candiolo, Italy. [Benelli M] Bioinformatics Unit, Oncology Department, Nuovo Ospedale-Santo Stefano, Prato, Italy. [De Cecco L] Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Serra V, Llop-Guevara A] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 37129948 |
dc.identifier.wos | 000996399300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |